Skip to main content

Table 4 Comparison of model selection and fit for viral suppression at 96 weeks

From: Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART

Analyses Model DIC pD Deviance Between study prop3 prop4
AgD NMA – Unadjusted Fixed 111.78 40.95 70.83 0.114 (0.005, 0.325) 6/96 6/96
One-stage IPD-AgD NMA – CD4 + HIV RNA + Male Fixed 102.45 43.99 58.46 0.077 (0.003, 0.254) 4/96 3/96
One-stage IPD-AgD NMA – CD4 + Male Fixed 101.17 42.98 58.19 0.085 (0.006, 0.263) 4/96 3/96
One-stage IPD-AgD NMA – CD4 + HIV RNA Fixed 103.91 43.03 60.88 0.094 (0.005, 0.297) 5/96 3/96
One-stage IPD-AgD NMA – HIV RNA + Male Fixed 100.66 42.97 57.69 0.072 (0.003, 0.238) 4/96 3/96
One-stage IPD-AgD NMA – CD4 Fixed 103.22 41.91 61.31 0.101 (0.007, 0.296) 4/96 3/96
One-stage IPD-AgD NMA – HIV RNA Fixed 99.43 42.04 57.39 0.074 (0.004, 0.241) 4/96 3/96
One-stage IPD-AgD NMA – Male Fixed 101.22 42.02 59.2 0.088 (0.006, 0.275) 4/96 3/96
  1. AgD Aggregate data, IPD Individual patient data, NMA Network meta-analysis, DIC Deviance information criterion, pD Effective number of parameters, prop3 Proportion of observations above deviance2 + leverage = 3, prop4 Proportion of observations above deviance2 + leverage = 4. Between-study heterogeneity obtained through the random-effects model, not the fixed-effect model if it was selected